Denali Therapeutics Inc. DNLI

Annual Quarterly

Q3 FY2026 · ended Sep 30, 2026 · Revenue $17.78M, +393.3% YoY · Filed Nov 3, 2026

Denali Therapeutics Inc. (DNLI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $17.8 million and net income of $70.1 million. Free cash flow was -$118.5 million. As of Sep 30, 2026 it held $1.0 billion in cash and investments and $35.2 million in total debt.

Revenue
$17.78M
+393.3% vs prior quarter
Net income
$70.13M
+155.3% vs year-ago quarter
Operating cash flow
$-117.44M
-9.5% vs year-ago quarter
Free cash flow
$-118.45M
-9.0% vs year-ago quarter
EPS
$0.37
+150.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
160.29M
+9.3% vs year-ago quarter
Net cash
$972.33M
Q3 FY2026
Operating margin
-713.0%
Q3 FY2026

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
DNLI (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
Large accelerated filer
SEC CIK
1714899

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Revenue
$17.8M
$3.6M
—
—
—
Operating income
-$126.8M
-$130.5M
-$137.4M
-$137.4M
-$137.4M
Net income
$70.1M
-$127.6M
-$128.4M
-$128.5M
-$126.9M
Diluted EPS
$0.37
-$0.68
-$0.69
-$0.73
-$0.74
Operating cash flow
-$117.4M
-$97.0M
-$131.2M
-$98.5M
-$107.3M
Free cash flow
-$118.5M
-$97.8M
-$133.7M
-$100.1M
-$108.7M
Total assets
$1.3B
$1.2B
$1.3B
$1.1B
$1.1B
Total liabilities
$329.6M
$322.8M
$339.9M
$131.1M
$129.4M
Stockholders' equity
$926.4M
$835.2M
$926.1M
$1.0B
$926.2M
Cash and investments
$1.0B
$940.0M
$1.1B
$966.2M
$872.9M
Total debt
$35.2M
$37.7M
$40.0M
$42.3M
$44.5M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 3, 2026 Sep 30, 2026
8-K Current report
Results of operations
 Nov 3, 2026 Nov 3, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 6, 2026 Aug 6, 2026
8-K Current report
Acquisition or sale of assets
 Jul 28, 2026 Jul 27, 2026
8-K Current report
Material agreement, Regulation FD disclosure
 Jun 18, 2026 Jun 12, 2026

All 789 Denali Therapeutics Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.